Country Club Bank Decreases Stock Position in Merck & Co., Inc. $MRK

Country Club Bank cut its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 1.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 87,562 shares of the company’s stock after selling 1,157 shares during the period. Country Club Bank’s holdings in Merck & Co., Inc. were worth $6,926,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC increased its holdings in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares in the last quarter. First Citizens Bank & Trust Co. boosted its holdings in shares of Merck & Co., Inc. by 67.0% during the 1st quarter. First Citizens Bank & Trust Co. now owns 83,216 shares of the company’s stock valued at $7,469,000 after acquiring an additional 33,378 shares during the last quarter. Werlinich Asset Management LLC boosted its holdings in shares of Merck & Co., Inc. by 9.9% during the 1st quarter. Werlinich Asset Management LLC now owns 28,120 shares of the company’s stock valued at $2,524,000 after acquiring an additional 2,530 shares during the last quarter. Foundation Resource Management Inc. grew its stake in shares of Merck & Co., Inc. by 46.8% in the first quarter. Foundation Resource Management Inc. now owns 186,197 shares of the company’s stock worth $16,713,000 after acquiring an additional 59,369 shares during the period. Finally, Baldwin Wealth Partners LLC MA raised its holdings in shares of Merck & Co., Inc. by 1.9% during the first quarter. Baldwin Wealth Partners LLC MA now owns 200,550 shares of the company’s stock valued at $18,001,000 after purchasing an additional 3,794 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MRK shares. Wells Fargo & Company dropped their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. Morgan Stanley cut their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $104.31.

Read Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $88.83 on Tuesday. The stock has a 50-day simple moving average of $82.96 and a two-hundred day simple moving average of $81.48. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $111.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The firm has a market capitalization of $221.88 billion, a PE ratio of 13.69, a P/E/G ratio of 0.92 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be given a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.